US Patent 7,320,969: Scope, Claims, Expiration, Orange Book Status, and Competitive Landscape

US Patent 7,320,969 covered an extended-cycle oral contraceptive regimen using 84 consecutive days of ethinyl estradiol plus levonorgestrel, followed by seven days of low-dose ethinyl estradiol. The commercial embodiment corresponds closely to Seasonique, which contains 30 micrograms of ethinyl estradiol and 150 micrograms of levonorgestrel during the 84-day contraceptive phase, followed by 10 micrograms of ethinyl estradiol for seven days.

The patent was a method-of-use patent, not a composition-of-matter patent. Its principal commercial claims focused on the 84/7 dosing schedule, the estrogen-only interval, and the specific 30-microgram ethinyl estradiol/150-microgram levonorgestrel combination. The patent’s Orange Book term ended in 2024, eliminating the principal US patent barrier associated with the claimed regimen. [1]

What does US Patent 7,320,969 cover?

US Patent 7,320,969 covers a contraceptive method that uses two sequential dosing phases:

Phase	Duration	Required active ingredients	Relevant dose
Combination phase	81 to 89 consecutive days	Estrogen plus progestin	Estrogen equivalent to 10-50 mcg ethinyl estradiol; 150 mcg levonorgestrel
Estrogen-only phase	2 to 8 consecutive days	Estrogen	Estrogen equivalent to 5-10 mcg ethinyl estradiol

The broadest independent claim requires:

A female in need of contraception.
Administration of estrogen and progestin for 81 to 89 consecutive days.
Administration of estrogen alone, or a dosage consisting essentially of estrogen, for 2 to 8 consecutive days.
An estrogen dose of approximately 10-50 micrograms of ethinyl estradiol equivalent during the combination phase.
Approximately 5-10 micrograms of ethinyl estradiol equivalent during the estrogen-only phase.
Approximately 150 micrograms of levonorgestrel during the combination phase.

The claims therefore require more than a conventional monthly oral contraceptive cycle. A product or regimen must practice the extended combination phase and the subsequent low-dose estrogen interval.

How strong is the independent claim in Patent 7,320,969?

Claim 1 is commercially important but structurally narrow in several respects.

Required 84-day or near-84-day combination phase

The claim requires 81 to 89 consecutive days of estrogen plus levonorgestrel. The dependent claims narrow this range to at least 84 days and, ultimately, exactly 84 days.

A conventional 21-day active-pill regimen followed by seven placebo days would not fall within the claim because it lacks the required 81-to-89-day combination phase.

Required estrogen-only interval

The second phase must last 2 to 8 consecutive days and must consist essentially of estrogen. A seven-day placebo interval would not satisfy this limitation because placebo tablets do not provide estrogen.

This limitation distinguishes the patent from extended-cycle products that use placebo tablets during the interval. It also distinguishes the claimed regimen from continuous products that do not include a defined estrogen-only phase.

Levonorgestrel limitation

The progestin must be levonorgestrel administered at approximately 150 micrograms per day. A regimen using drospirenone, desogestrel, norethindrone, norgestrel, or another progestin would not literally satisfy this limitation.

Whether a different progestin could be reached under the doctrine of equivalents would depend on the factual record, prosecution history, claim construction, and the extent to which levonorgestrel was treated as a limiting selection during prosecution.

"About" dose language

The use of "about" creates potential numerical flexibility around the stated doses. It does not remove the requirement that the regimen contain approximately 150 micrograms of levonorgestrel or the specified ethinyl estradiol-equivalent doses.

A product containing 150 micrograms of levonorgestrel is the clearest target. A materially different dose would present a stronger noninfringement position, although the outcome would depend on the intrinsic evidence and prosecution history.

What do claims 17, 18, and 19 protect?

Claims 17, 18, and 19 are the most commercially specific claims.

Claim	Combination-phase estrogen	Combination-phase progestin	Estrogen-only phase	Route and schedule
17	10-50 mcg ethinyl estradiol	150 mcg levonorgestrel	10 mcg ethinyl estradiol	Oral, monophasic, 84/7
18	10-30 mcg ethinyl estradiol	150 mcg levonorgestrel	10 mcg ethinyl estradiol	Oral, monophasic, 84/7
19	30 mcg ethinyl estradiol	150 mcg levonorgestrel	10 mcg ethinyl estradiol	Oral, monophasic, 84/7

Claim 19 is the closest claim to the Seasonique regimen. It requires:

84 consecutive days;
30 micrograms of ethinyl estradiol daily;
150 micrograms of levonorgestrel daily;
seven consecutive days;
10 micrograms of ethinyl estradiol daily;
oral, monophasic administration.

Claims 17 and 18 have broader estrogen coverage. Claim 17 reaches 10-50 micrograms, while claim 18 is limited to 10-30 micrograms. Claim 19 is narrower but maps most directly to the commercial 30/150 plus 10 microgram regimen.

What formulations and dosage forms are protected?

The patent claims oral and transdermal administration.

Oral formulations

Claims 15 and 17-19 expressly cover orally administered regimens. The oral claims can reach:

tablets;
capsules;
sequential blister packs;
monophasic active tablets;
separate estrogen-only tablets;
combination products packaged with a seven-day low-dose estrogen phase.

The claims are directed to the method of administration rather than to a particular tablet composition. Conventional pharmaceutical excipients would generally not avoid the claims if the active ingredients, doses, route, and schedule remain within the claim limitations.

Transdermal formulations

Claim 16 covers transdermal administration. This creates potential coverage for patches or other transdermal systems delivering the required estrogen and levonorgestrel schedule.

The practical scope of claim 16 is narrower than the oral commercial claims because transdermal levonorgestrel delivery at the claimed regimen would require a workable delivery system. The patent does not, based on the listed claims, establish a separate composition-of-matter right in a particular patch, adhesive, reservoir, or rate-control technology.

"Consisting essentially of estrogen"

The estrogen-only phase is not necessarily limited to an estrogen molecule alone. "Consisting essentially of" generally permits inactive ingredients and components that do not materially affect the basic and novel characteristics of the dosage.

A formulation containing another active pharmaceutical ingredient during the estrogen-only interval could create a claim-construction issue. The risk would be higher if the additional active ingredient materially altered the pharmacologic purpose or operation of the estrogen-only phase.

Does the patent cover antidepressant co-administration?

Claims 10-14 add antidepressant embodiments.

The patent claims an antidepressant administered:

with the estrogen-only dose;
intermittently;
once;
once weekly; or
for five to eight days in combination with the estrogen-only phase.

Claim 12 identifies fluoxetine hydrochloride at an amount equivalent to approximately 5-120 milligrams. Claim 14 also specifically identifies fluoxetine hydrochloride.

These claims create a secondary method-of-use layer for managing symptoms associated with the estrogen-only interval. They do not convert the patent into a broad patent on fluoxetine, antidepressants, or contraception. The claims require the antidepressant to be used in the context of the claimed extended-cycle contraceptive regimen.

The antidepressant claims would face several practical limitations:

The underlying 84/7 contraceptive regimen must be practiced.
The antidepressant timing must satisfy the selected dependent claim.
The dose and active ingredient must fall within the claim.
Medical records or prescribing instructions may be necessary to establish method performance in litigation.

When did US Patent 7,320,969 lose exclusivity?

The Orange Book-listed patent term ended on or about September 20, 2024. The patent therefore no longer provides a live US patent exclusion right after that date, subject to any case-specific issue involving a terminal disclaimer, patent-term adjustment, or enforceability ruling. FDA Orange Book listings historically identified US 7,320,969 in connection with Seasonique and related levonorgestrel/ethinyl estradiol products. [1]

The patent was not a biologic patent and did not carry biosimilar exclusivity. Its commercial impact was based on Hatch-Waxman patent listing and potential generic certification, not on the Public Health Service Act biosimilar pathway.

What was the FDA and Orange Book status?

Seasonique was approved by FDA as an extended-cycle oral contraceptive. The product used 84 days of levonorgestrel/ethinyl estradiol followed by seven days of ethinyl estradiol. The NDA and subsequent abbreviated applications created the relevant regulatory framework for generic competition. [2]

The patent’s regulatory significance was tied to:

the listed drug’s 84/7 regimen;
the low-dose estrogen interval;
the identified active ingredients;
the patent listing in the Orange Book;
Paragraph IV certifications by generic applicants.

The patent did not prevent FDA approval of unrelated contraceptive products using different progestins, different cycle lengths, placebo intervals, or continuous dosing.

Which companies challenged the patent?

Generic-drug challenges to Seasonique-related patents arose through the Hatch-Waxman process. Publicly reported litigation involved Warner Chilcott and Teva in connection with generic Seasonique patent disputes. The disputes concerned whether generic versions could be approved or launched before expiration of the listed patent rights. [3]

The relevant competitive pattern was typical for extended-cycle contraceptives:

Party type	Commercial objective
Brand sponsor	Preserve the Seasonique market and delay generic entry
ANDA applicant	Obtain approval through a Paragraph IV certification or await patent expiry
FDA	Determine approval eligibility under the ANDA pathway
Federal courts	Decide infringement, validity, enforceability, and launch rights

A Paragraph IV certification is not itself an infringement finding. It is an assertion that the listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. The brand sponsor’s timely patent suit can trigger a statutory FDA approval stay, generally for up to 30 months under Hatch-Waxman. [4]

Were there settlement agreements?

The commercial record includes patent disputes involving generic applicants and Seasonique-related rights. A settlement agreement may resolve launch timing without producing a final merits judgment on validity or infringement.

A settlement can provide an authorized or licensed launch date, but it does not necessarily establish that the patent claims were valid or infringed. The business effect depends on:

the agreed launch date;
whether the generic receives a license;
supply or authorized-generic provisions;
restrictions on at-risk launch;
treatment of later patent challenges.

The patent’s 2024 expiration ultimately removed the principal timing value of the patent, regardless of earlier settlement arrangements.

How does Patent 7,320,969 compare with competing contraceptive patent estates?

Product or regimen	Typical schedule	Progestin	Estrogen-only interval	Relationship to Patent 7,320,969
Seasonique-type regimen	84/7	Levonorgestrel	Yes, 10 mcg EE	Closest commercial embodiment
Seasonale-type regimen	84/7	Levonorgestrel	Generally placebo interval	May avoid the estrogen-only limitation
LoSeasonique-type regimen	84/7	Levonorgestrel	Low-dose estrogen interval	Dose differences may affect claim coverage
Yaz-type regimen	24/4 or other	Drospirenone	No matching 84/7 structure	Outside the levonorgestrel limitation
NuvaRing-type regimen	Monthly vaginal delivery	Etonogestrel	No matching oral 84/7 regimen	Outside route and active-ingredient limitations
Continuous oral regimens	Continuous	Various	No defined estrogen-only phase	May avoid the sequential-phase limitation

The most important design-around variables are:

replacing levonorgestrel with another progestin;
using placebo rather than estrogen during the interval;
changing the combination phase outside 81-89 days;
changing the estrogen-only phase outside 2-8 days;
using a different route;
using a nonmonophasic regimen;
changing the dose outside the claimed ranges.

Changing only the brand name, tablet color, packaging, or excipient system would not ordinarily address the core claim limitations.

What generic launch risks existed?

Before expiration, a generic applicant targeting the Seasonique regimen faced four principal risks:

patent infringement litigation;
a 30-month FDA approval stay after timely suit;
damages or injunctive relief for an at-risk launch;
settlement restrictions affecting launch timing.

After expiration, the principal patent-based launch risk associated with US 7,320,969 fell away. Remaining barriers are regulatory, manufacturing, supply-chain, formulation, and commercial rather than exclusion rights under this patent.

A generic product still must meet FDA requirements for pharmaceutical equivalence, bioequivalence, labeling, manufacturing controls, and product-specific approval. Patent expiration does not eliminate those obligations.

What manufacturing and intellectual-property barriers remain?

Patent 7,320,969 does not appear, from the listed claims, to claim a specialized manufacturing process, crystalline form, dosage-unit geometry, blister-pack architecture, or excipient system.

Potential residual barriers may include:

separate patents covering a different formulation;
packaging or delivery-system patents;
process patents;
trademark restrictions;
regulatory exclusivity unrelated to this patent;
manufacturing validation;
supply of levonorgestrel and ethinyl estradiol;
market access and pharmacy substitution.

These barriers must be assessed separately from the 84/7 method claims.

What licensing deals affected the patent?

The patent was associated with the commercial development and marketing of Seasonique and related products through corporate ownership and product-rights transfers. Corporate acquisitions or product divestitures do not necessarily establish a third-party patent license.

No broad public license covering the entire contraceptive field follows from US 7,320,969. Any license would need to be evaluated from the relevant assignment, merger, settlement, or commercialization agreement.

Key Takeaways

US 7,320,969 is a method-of-use patent for an extended-cycle contraceptive regimen.
The core schedule is 84 days of ethinyl estradiol plus 150 micrograms of levonorgestrel, followed by seven days of low-dose ethinyl estradiol.
Claim 19 is the closest claim to the commercial Seasonique 30/150 plus 10 microgram regimen.
The patent also covers selected antidepressant co-administration, including fluoxetine hydrochloride.
Oral and transdermal routes are claimed, but the commercial focus was oral contraception.
The patent did not claim levonorgestrel, ethinyl estradiol, fluoxetine, or a general contraceptive composition.
Product designs using placebo intervals, different progestins, different cycle lengths, or continuous dosing may avoid the literal claim limitations.
The Orange Book-listed patent term ended in or about September 2024.
The patent did not create biosimilar risk because the products are small-molecule drugs.
Current generic competition is primarily constrained by FDA approval, manufacturing, formulation, supply, and commercial execution rather than this expired patent.

Frequently Asked Questions

Does Patent 7,320,969 cover Seasonale?

Not necessarily. Seasonale-type products generally use an extended active-pill schedule followed by placebo tablets. Patent 7,320,969 requires an estrogen-only interval, which is a material distinction.

Does the patent cover LoSeasonique?

Potentially, depending on the exact estrogen and levonorgestrel doses, schedule, formulation, and product labeling. A dose outside the claimed ranges may provide a noninfringement position, but the analysis requires claim construction and comparison with the approved labeling.

Can a generic launch an 84/7 contraceptive after patent expiration?

Yes, subject to FDA approval and compliance with any other unexpired patents or regulatory protections. Expiration of US 7,320,969 removes the principal exclusion right created by that patent.

Is the patent a composition-of-matter patent?

No. The claims provided are method claims requiring a specific contraceptive administration sequence, doses, ingredients, and, in some claims, route of administration.

Does the patent cover transdermal contraception broadly?

No. Claim 16 reaches the claimed regimen when administered transdermally. It does not broadly cover all contraceptive patches or all transdermal estrogen-progestin products.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,320,969, Contraceptive regimen. USPTO. https://patents.google.com/patent/US7320969
U.S. Food and Drug Administration. (2018). ANDA submissions: Refuse-to-receive standards. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-submissions-generics-requirements-controls-and-review-process

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1453521	⤷ Start Trial	122015000093	Germany	⤷ Start Trial
European Patent Office	1453521	⤷ Start Trial	CA 2016 00016	Denmark	⤷ Start Trial
European Patent Office	1453521	⤷ Start Trial	93156	Luxembourg	⤷ Start Trial
European Patent Office	1453521	⤷ Start Trial	300814	Netherlands	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,320,969

Summary for Patent: 7,320,969